



# A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza

Tor Kristian Andersen,<sup>a,b</sup> Fan Zhou,<sup>a,c</sup> Rebecca Cox,<sup>a,c,d</sup> Bjarne Bogen,<sup>a,b,e</sup> Gunnveig Grødeland<sup>a,b</sup>

K. G. Jebsen Centre for Influenza Vaccine Research<sup>a</sup> and Institute of Clinical Medicine,<sup>b</sup> University of Oslo and Oslo University Hospital, Oslo, Norway; Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway<sup>c</sup>; Department of Research and Development, Haukeland University Hospital, Bergen, Norway<sup>d</sup>; Centre for Immune Regulation, University of Oslo, Oslo, Norway<sup>e</sup>

**ABSTRACT** Zoonotic influenza H7 viral infections have a case fatality rate of about 40%. Currently, no or limited human to human spread has occurred, but we may be facing a severe pandemic threat if the virus acquires the ability to transmit between humans. Novel vaccines that can be rapidly produced for global distribution are urgently needed, and DNA vaccines may be the only type of vaccine that allows for the speed necessary to quench an emerging pandemic. Here, we constructed DNA vaccines encoding the hemagglutinin (HA) from influenza A/chicken/Italy/13474/99 (H7N1). In order to increase the efficacy of DNA vaccination, HA was targeted to either major histocompatibility complex class II molecules or chemokine receptors 1, 3, and 5 (CCR1/3/5) that are expressed on antigen-presenting cells (APC). A single DNA vaccination with APC-targeted HA significantly increased antibody levels in sera compared to nontargeted control vaccines. The antibodies were confirmed neutralizing in an H7 pseudotype-based neutralization assay. Furthermore, the APC-targeted vaccines increased the levels of antigen-specific cytotoxic T cells, and a single DNA vaccination could confer protection against a lethal challenge with influenza A/turkey/Italy/3889/1999 (H7N1) in mice. In conclusion, we have developed a vaccine that rapidly could contribute protection against a pandemic threat from avian influenza.

**IMPORTANCE** Highly pathogenic avian influenza H7 constitute a pandemic threat that can cause severe illness and death in infected individuals. Vaccination is the main method of prophylaxis against influenza, but current vaccine strategies fall short in a pandemic situation due to a prolonged production time and insufficient production capabilities. In contrast, a DNA vaccine can be rapidly produced and deployed to prevent the potential escalation of a highly pathogenic influenza pandemic. We here demonstrate that a single DNA delivery of hemagglutinin from an H7 influenza could mediate full protection against a lethal challenge with H7N1 influenza in mice. Vaccine efficacy was contingent on targeting of the secreted vaccine protein to antigen-presenting cells.

**KEYWORDS** APC-targeting, DNA vaccine, avian viruses, hemagglutinin, influenza, pandemic influenza

Highly pathogenic avian influenza viruses (HPAIV) represent a potential pandemic threat. As of June, 2017, the World Health Organization has reported a total of 1,533 laboratory-confirmed cases of human infection with avian influenza H7N9, with a mortality rate of nearly 40% (1). A majority of these cases arose from zoonotic transmissions at the human-animal interface, with limited human-to-human transmission. Viruses isolated from human cases, perhaps including secondary cases of human transmissions, show only a few accumulated mutations in surface glycoproteins (2).

Received 7 August 2017 Accepted 18 September 2017

Accepted manuscript posted online 20 September 2017

**Citation** Andersen TK, Zhou F, Cox R, Bogen B, Grødeland G. 2017. A DNA vaccine that targets hemagglutinin to antigen-presenting cells protects mice against H7 influenza. *J Virol* 91:e01340-17. <https://doi.org/10.1128/JVI.01340-17>.

**Editor** Bryan R. G. Williams, Hudson Institute of Medical Research

**Copyright** © 2017 Andersen et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Gunnveig Grødeland, [gunnveig.grodeland@medisin.uio.no](mailto:gunnveig.grodeland@medisin.uio.no). B.B. and G.G. contributed equally to this article.

Thus, it is difficult to predict the antigenic determinants of transmissibility that are needed to break the zoonotic barrier and also how these would influence the viral pathogenicity in humans (3). However, the human population is presently serologically naive toward H7 influenza; therefore, the potential acquisition of mutations enabling efficient human-to-human transmission could have a devastating effect.


Conventional vaccine design relies on an extensive surveillance system to determine which influenza strains will be included in the next season's influenza vaccine. The 2009 pandemic demonstrated that the development and vaccine production process could be completed in about 6 months, which represents a best-case scenario (4). Both the 2009 H1N1 pandemic and the 2013 HPAIV H7N9 emergence in China (5) demonstrate that it is difficult to predict which influenza strain will cause the next pandemic and that conventional influenza vaccines are not sufficient in the face of a pandemic outbreak. Novel vaccine formats that can rapidly be produced and quickly induce an immune response upon a novel pandemic threat are urgently needed (6–8).

The multifaceted pathogenicity of HPAIV is maintained by two major determinants. First, the hemagglutinin (HA) in HPAIV has a receptor binding preference for  $\alpha$ 2,3-linked sialic acid that is abundant on the gut epithelia of aquatic birds (9). In humans,  $\alpha$ 2,3- and  $\alpha$ 2,6-linked sialic acid receptors dominate in the lower and upper respiratory tract, respectively. Efficient human-to-human transmission of influenza virus is dependent on viral replication in the upper respiratory tract (10). The viral preference for  $\alpha$ 2,3-linked sialic acid receptors thus represents a natural barrier for zoonotic and human-to-human transmission with HPAIV (11). However, certain H7 isolates have been demonstrated to bind both sialic acid receptors (12–14), forming a breach in the zoonotic barrier (15). Second, HA in HPAIV have acquired a multibasic cleavage site (MBCS) (16–19). HA cleavage is necessary for influenza infectivity, and where seasonal influenza HAs are only cleaved by tissue-restricted proteases, HPAIV HAs can be cleaved by ubiquitous cellular proteases. Thus, the potential pathogenicity of an HPAIV is enhanced since the virus evades tissue-restricted replication (20–23).

DNA vaccines can be rapidly produced but are typically hampered by reduced immunogenicity. Previously, we demonstrated that a single DNA vaccination with HA from influenza H1N1 targeted to major histocompatibility complex class II (MHC-II) molecules on antigen-presenting cells (APCs) confers sterilizing immunity against influenza challenge in mice (24, 25). Furthermore, translation into larger animals confirmed the increased immunogenicity after APC-targeting of antigen (26). In addition to MHC-II targeting, chemokines are attractive targeting units due to the chemotactic recruitment of, among others, dendritic cells (DCs), macrophages, and NK cells, and chemokines can channel recruitment of internalized antigen to MHC-I and MHC-II presentation pathways (27–31). Here, we extended these experiments to vaccination against HPAIV H7. After targeting of HA from A/chicken/Italy/13474/1999 (H7N1) or A/turkey/Italy/3889/1999 (H7N1) to MHC-II molecules or chemokine receptors 1, 3, and 5 (CCR1/3/5) expressed on APC, we demonstrate that a single DNA vaccination can confer protection against a lethal H7N1 challenge in mice.

## RESULTS

**Construction and characterization of APC-targeted influenza vaccines.** Previously, we demonstrated that a single DNA immunization with APC-targeted HA from H1N1 influenzas provided protection against a lethal challenge in mice (23, 24). A key feature of the vaccine was the bivalent display of antigens that were linked via a dimerization unit containing the hinge region and C<sub>H</sub>3 from human IgG3 to targeting units specific for receptors on APCs (Fig. 1A) (28, 32). Here, we inserted HA from A/chicken/Italy/13474/99 (H7N1) (amino acids 19 to 536 [aa19-563]) into the same vaccine format and targeted HA toward either chemokine receptors 1, 3, and 5 (CCR1/3/5), or MHC-II molecules (Fig. 1A). To target HA to MHC-II molecules, we used a single-chain-variable fragment (scFv) that was specific for I-E<sup>d</sup> (denoted  $\alpha$ MHCII-H7), whereas the chemokine Mip1 $\alpha$  was used for targeting of HA to CCR1/3/5 (denoted Mip1 $\alpha$ -H7). As nontargeted controls, we constructed a vaccine where the APC-specific



**FIG 1** Characterization of vaccine proteins. (A) Schematic illustration of a dimeric vaccine protein. The targeting units, either an scFv specific for mouse I-E<sup>d</sup> ( $\alpha$ MHCII), the chemokine MIP1 $\alpha$  (Mip1 $\alpha$ ), or a scFv specific for the hapten NIP ( $\alpha$ Nip; nontargeted control), are connected to HA via a dimerization unit containing the hinge and C<sub>H</sub>3 domain from human IgG3. (B) Western blot of supernatants from 293E cells transfected with the indicated vaccine plasmids. Molecular sizes and corresponding structures are indicated. (C) Vaccine proteins in supernatants from transiently transfected 293E cells were detected in an ELISA specific for HA from A/Shanghai/1/2013 (H7N9). (D) Binding of vaccine proteins to B cells (CD19<sup>+</sup>), macrophages (F4/80<sup>+</sup> CD64<sup>+</sup>), DCs (Lin<sup>-</sup> CD11c<sup>hi</sup>) divided into conventional DC1 (CD24<sup>+</sup>) and conventional DC2 (CD11b<sup>+</sup>), and T cells (CD3<sup>+</sup>) from BALB/c splenocytes.


targeting unit was replaced with a scFv against the hapten Nip (denoted  $\alpha$ Nip-H7) and a plasmid encoding only HA (denoted H7). In some experiments, we also used the previously described MHC-II-targeted vaccine with HA from influenza A/Puerto Rico/8/34 (H1N1) (24) to control for antigen specificity (denoted  $\alpha$ MHCII-H1).

Supernatants from 293E cells transiently transfected with the different vaccine plasmids confirmed the appropriate size (Fig. 1B) and *in vitro* expression of the secreted vaccine proteins (Fig. 1C). The nontargeted control,  $\alpha$ Nip-H7, exhibited an  $\sim$ 2-fold-higher protein expression level than the other vaccines, potentially providing a concentration dependent benefit for the *in vivo* DNA vaccinations. In order to verify efficient binding of the vaccine proteins to APC, we assayed their binding profiles to splenocytes (Fig. 1D). Vaccines targeting MHC-II molecules ligated B cells, macrophages, and conventional DC1 and DC2, whereas CCR1/3/5-targeted vaccines ligated macrophages and conventional DC1. As expected, nontargeted control failed to ligate any of the cell types investigated, and T cells were not bound by either of the constructs.

**An intact multibasic cleavage site increases antibody responses.** Conventional production of vaccines against HPAIV depends on removal of the MBCS in order to prevent disease and potential lethality embryonated hens' eggs (4, 33). In contrast, this is not a problem for the synthetic production of DNA vaccines. Therefore, we wanted to compare the immunogenicities of APC-targeted H7 antigens with the intact or deleted MBCS sequences, and we cloned an HA with a deleted MBCS into the MHC-II-targeted vaccine format described above. The vaccine displaying the deleted MBCS sequence was denoted  $\alpha$ MHCII-H7 $\Delta$  (Fig. 2A).

The correct size and expression of  $\alpha$ MHCII-H7 $\Delta$  was confirmed (Fig. 2C and D). Since endogenous proteases in 293E cells will cleave H7 with intact MBCS (22), we observed bands corresponding to cleavage of HA0 into HA1 ( $\sim$ 115 kDa, including the targeting domain and dimerization unit) and HA2 ( $\sim$ 35 kDa) for  $\alpha$ MHCII-H7, but not for  $\alpha$ MHCII-H7 $\Delta$  (Fig. 2B and C). The *in vitro* expression levels of  $\alpha$ MHCII-H7 $\Delta$  were slightly higher than that of  $\alpha$ MHCII-H7 (Fig. 2D). Nevertheless, *in vivo* DNA vaccination of mice showed that  $\alpha$ MHCII-H7 induced significantly higher IgG titers than did  $\alpha$ MHCII-H7 $\Delta$  (Fig. 2E). The difference was significant already 1 week postvaccination, and antibody levels remained higher at least 4 weeks postvaccination. Taken together, the data suggest that H7 with an intact MBCS could offer an immune-potentiating effect that is maintained when targeting of HA to MHC-II molecules in mice. Thus, further experiments were performed with  $\alpha$ MHCII-H7.


**Rapidly increased IgG levels after MHC-II-targeted vaccination.** Since the rapid induction of protection is crucial for pandemic prevention, mice were DNA vaccinated only once, and antibody responses in serum were assessed for 5 weeks postvaccination.



**FIG 2** MHC-II-targeted HA vaccination with or without a multibasic cleavage site. (A) Alignment of the MBCS in H7 and the deleted corresponding sequence in H7Δ. (B) Schematic illustration depicting the vaccine monomer with indicated MBCS in HA. The full-length vaccine monomer is ~150 kDa and HA2 is ~35 kDa, resulting in fragments of ~115 and ~35 kDa, respectively, under reducing conditions. (C) Western blot of secreted vaccine proteins (indicated) under reducing conditions in supernatant from transiently transfected 293E cells. (D) Binding of secreted  $\alpha$ MHCII-H7 or  $\alpha$ MHCII-H7Δ proteins in supernatants from transiently transfected 293E cells detected in an ELISA specific for HA from A/Shanghai/1/2013 (H7N9). (E) Mice ( $n = 6$ /group) were vaccinated i.d. with plasmid DNA encoding either  $\alpha$ MHCII-H7 or  $\alpha$ MHCII-H7Δ, or NaCl, and IgG in sera measured in ELISA against recombinant HA from influenza A/Shanghai/1/2013 (H7N9) at weeks 1, 2, and 4 postvaccination. \*,  $P < 0.05$  (two-tailed Mann-Whitney test).

Mice were immunized with plasmids targeting H7 toward either CCR1/3/5 or MHC-II molecules or with nontargeted control vaccines ( $\alpha$ Nip-H7 and H7). In addition, a group was vaccinated with  $\alpha$ MHCII-H1 to control for specificity (Fig. 3A). To generalize the effect of APC targeting, parallel experiments were performed in BALB/c mice and the CB6F1 hybrid strain. Results demonstrated that IgG responses were significantly elevated already the first weeks after vaccination with  $\alpha$ MHCII-H7 in both BALB/c (Fig. 3B) and CB6F1 mice (Fig. 3C). The antibody responses after vaccination with Mip1 $\alpha$ -H7 were only significantly increased above that of the nontargeted controls at week 4 postvaccination for both mouse strains. As expected,  $\alpha$ MHCII-PR8 did not induce any antibodies that cross-reacted with influenza H7. The same trends were observed when the vaccines were delivered intramuscularly (i.m.) in BALB/c (data not shown).

In order to assess the neutralizing antibody response, sera from weeks 2 and 4 postvaccination in BALB/c were examined in a pseudotype-based neutralization assay against A/FPV/Rostock/1934(H7N1) HA and neuraminidase (NA) pseudotype virus. The results demonstrated that a single vaccination with  $\alpha$ MHCII-H7 significantly increased 50% inhibitory concentration ( $IC_{50}$ ) levels in sera at both 2 and 4 weeks postvaccination compared to the nontargeted control vaccines ( $\alpha$ NIP-H7 and H7) (Fig. 3D). Furthermore, significantly enhanced  $IC_{50}$  levels were observed in sera collected 4 weeks after vaccination with Mip1 $\alpha$ -H7, compared to the nontargeted controls. The results for both  $\alpha$ MHCII-H7 and Mip1 $\alpha$ -H7 corresponded to the increases that were observed in enzyme-linked immunosorbent assay (ELISA;  $P < 0.05$ , Spearman correlation  $IC_{50}$  and serum titers) (Fig. 3B and D). When extending the analyses to examinations of  $IC_{90}$  titers, vaccination with  $\alpha$ MHCII-H7 significantly increased the levels of protective anti-




**FIG 3** Antibody responses after a single DNA vaccination. (A) Schematic illustration of the experiment. Briefly, BALB/c ( $n = 12/\text{group}$ ) or CB6F1 mice ( $n = 6/\text{group}$ ) were DNA vaccinated once i.d. with the indicated vaccine plasmids. Sera were collected up to 4 weeks postvaccination from BALB/c (B) and CB6F1 (C), and antibody responses were measured by ELISA against recombinant HA from influenza A/Shanghai/1/2013 (H7N9). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  (two-tailed Mann-Whitney test). (D) Sera from BALB/c from weeks 2 and 4 were pooled by group and assayed in a pseudotype microneutralization assay against A/FPV/Rostock/1934 (H7N1). Neutralization curves were fitted with GraphPad Prism 6 software, and the  $IC_{50}$  and  $IC_{90}$  titers were calculated. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  (extra sum-of-squares F test).

bodies compared to nontargeted controls. Taken together, the data demonstrated that αMHCII-H7 is superior at induction of neutralizing antibodies compared to Mip1α-H7 and nontargeted controls.

**Vaccine induced production of IFN-γ-secreting cells and cytotoxic T lymphocytes.** Although antibodies may block an influenza infection, T cells can clear already infected cells. Thus, the different DNA vaccines were assessed for their ability to induce sustained IFN-γ-secreting cells and cytotoxic T lymphocytes (CTL) after immunization. Splenocytes were harvested 8 weeks postvaccination and restimulated with recombinant HA from H7N9 influenza. The results demonstrated that mice receiving either αMHCII-H7 or Mip1α-H7 induced significantly higher levels of IFN-γ-secreting cells compared to the nontargeted controls (Fig. 4A). The enhanced induction was specific for H7, since restimulation with HA from other influenza A subtypes failed to increase IFN-γ production. As an additional control, αMHCII-H1 increased the levels of IFN-γ-secreting cells only after stimulation with HA from H1N1 influenza (Fig. 4B).

To further address whether the increase in IFN-γ-secreting cells could be interpreted as increased CTL activity *in vivo*, we retrovirally transduced an A20 mouse B lymphoma cell line to express cytosolic H7 and GFP, or mCherry as a control. At week 5 postvaccination, the cell lines were injected into BALB/c mice, and the ratio between green fluorescent protein (GFP)- and mCherry-positive cells was investigated 16 h later by



**FIG 4** Induction of T cells after a single immunization. BALB/c mice ( $n = 6/\text{group}$ ;  $n = 3/\text{group}$  for NaCl and H1 controls) were DNA vaccinated i.m. with plasmids encoding the indicated vaccines. Spleens were harvested at 8 weeks postvaccination. Splenocytes were restimulated with recombinant HA from A/Shanghai/1/2013(H7N9) (A) or HA from either A/Shanghai/1/2013(H7N9), A/Vietnam/1194/2004(H5N1), or A/Puerto Rico/8/34(H1N1) (B), and the numbers of IFN- $\gamma$ -secreting cells were evaluated. (C) BALB/c mice ( $n = 6/\text{group}$ ) were vaccinated i.d. with plasmid DNA encoding the indicated vaccines. After 5 weeks,  $5 \times 10^6$  A20 cells expressing cytosolic H7 and GFP and  $5 \times 10^6$  A20 cells expressing cytosolic mCherry were injected i.v. The prevalences of GFP- or mCherry-positive cells were assessed 16 h later, and the killing ratios were calculated. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  (two-tailed Mann-Whitney test).


flow cytometry. The killing ratios were calculated by comparing the remaining GFP population to the control population expressing mCherry (Fig. 4C). Both APC-targeted vaccines induced significant CTL responses, and in correspondence with the enzyme-linked immunospot assay (ELISPOT) data, CCR1/3/5-targeting induced a higher T-cell response compared to the MHC-II-targeted vaccine. In sum, the data demonstrated that targeting of HA to APCs significantly increased the vaccine induced T-cell responses and that they can participate in protection against an influenza infection.

**A single APC-targeted DNA vaccination can protect mice from a lethal influenza challenge.** In order to examine whether the APC-targeted vaccines could rapidly confer protection against influenza, mice were DNA immunized once intradermally (i.d.) and then challenged with a lethal dose of influenza A/turkey/Italy/3889/1999 (H7N1) 5 weeks after vaccination. Mice that received the APC-targeted vaccines showed significantly less morbidity compared to the nontargeted controls, and both BALB/c (Fig. 5A), and CB6F1 mice (Fig. 5B) were fully protected against influenza. In contrast, mice that received saline or nontargeted controls rapidly lost weight, and 40 to 60% of the mice receiving the nontargeted control vaccines had to be euthanized within 8 days post-challenge.

The influenza strain used for challenge has some sequence differences compared to the vaccine strain. In order to examine protection in a homologous challenge model, we also immunized mice with HA from A/turkey/Italy/3889/1999 (H7N1) and challenged them with this strain 5 weeks later (Fig. 5C). Mice receiving APC-targeted vaccines were fully protected against the lethal influenza challenge, in contrast to the nontargeted control vaccines. For the heterologous challenge experiments above (Fig. 5A and B), APC targeting of HA significantly improved protection against the influenza challenge compared to the nontargeted control vaccines, but we also observed an increased weight loss in mice receiving MHC-II-targeted HA compared to the group vaccinated with Mip1 $\alpha$ -H7. Here, we observed no significant difference in weight loss after MHC-II- and CCR1/3/5-targeted vaccination in the homologous challenge (Fig. 5C).

In order to further examine the differences in protection after vaccination with MHC-II- and CCR1/3/5-targeted HA, we set up an experiment examining lung pathology after viral challenge in BALB/c mice. Thus, mice were immunized with HA from






**FIG 5** Viral challenge of DNA-immunized mice. BALB/c mice ( $n = 6$  to  $12$ /group) or CB6F1 mice ( $n = 6$ /group) were vaccinated with  $25 \mu\text{g}$  of DNA i.d. and challenged with  $20 \times \text{LD}_{50}$  of mouse-adapted A/turkey/Italy/3889/1999 (H7N1) at week 5 postvaccination. The body weight (upper panels) was measured after challenge to assess morbidity, and survival curves (lower panels) are shown for mice receiving the indicated vaccines from BALB/c mice (A) and CB6F1 mice (B). (C) BALB/c mice were vaccinated with vaccines encoding the HA antigen A/turkey/Italy/3889/1999 (H7N1) homologous to the challenge strain and challenged at week 5 postvaccination. Weight curves: \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  (two-way ANOVA). Survival curves: \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  (Gehan-Breslow-Wilcoxon test). (D) Representative micrographs of H&E-stained sections of lungs from each group from the experiment in panel A collected 7 days postchallenge. Scale bar,  $250 \mu\text{m}$ .

A/chicken/Italy/13474/1999 (H7N1) and challenged 5 weeks later with A/turkey/Italy/3889/1999 (H7N1). At day 7 postchallenge, lungs were harvested, sectioned and stained with hematoxylin and eosin (H&E). Lungs harvested from control mice receiving NaCl and nontargeted control vaccines displayed histiocytic alveolitis, interstitial pneumonia, and edema. In contrast, mice receiving APC-targeted vaccines had healthy lungs with only minor lung pathology (Fig. 5D). Further, we observed that lungs collected from mice vaccinated with Mip1 $\alpha$ -H7 showed more cellular infiltration and lung pathology compared to mice vaccinated with  $\alpha\text{MHCII-H7}$ .

**Targeted vaccines induce T-cell responses that contribute to protection against viral challenge.** In order to investigate whether the main mediator of protection was antibodies or T cells, immunized mice were depleted of CD4<sup>+</sup> and CD8<sup>+</sup> T cells just prior to a lethal influenza challenge (Fig. 6). The depletion was maintained by injections of CD4- and CD8-depleting antibodies every other day and was determined to have an efficacy level of  $>99\%$  (data not shown). T-cell-depleted mice showed no significant increase in mortality compared to mice receiving isotype matched control antibodies. This demonstrated that the induced antibodies were protective. However, recovery after infection was significantly impaired in T-cell-depleted mice, as shown by the significant differences in morbidity that were observed during the second week after infection. The experiment highlights the importance of T cells in clearing a heterologous influenza infection. In conclusion, the APC-targeted vaccination induced both antibodies and T cells that contribute to protection against influenza.



**FIG 6** Viral challenge of DNA-immunized mice after depletion of T cells. Mice ( $n = 8$  to  $10$ /group) were DNA vaccinated i.d. with the indicated vaccines and then challenged with  $20 \times LD_{50}$  A/turkey/Italy/3889/1999 (H7N1) 5 weeks postvaccination. Two days prior to challenge—and every other day until completion of the experiment—mice were injected i.p. with either CD4 and CD8 depleting MAbs or isotype-matched MAbs. Starting at the day of challenge (D0), weight was monitored in mice vaccinated with Mip1 $\alpha$ -H7 (A) or  $\alpha$ MHCII-H7 (B). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  (two-way ANOVA). (C) Survival curves for mice in panels A and B. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  (Gehan-Breslow-Wilcoxon test).

## DISCUSSION

In the event of a pandemic outbreak of HPAIV, a vaccine platform capable of launching a quick production and response is crucial. It is essential to rapidly induce protective immunity in the population to limit viral spread and disease. We have here demonstrated that DNA vaccines targeting HA from HPAIV H7 to APCs in mice represent a potential vaccine candidate for induction of rapid immunity. Importantly, the APC-targeted DNA vaccines could mediate protection in mice that were challenged with a lethal dose of influenza H7N1 virus only 5 weeks after vaccination.

We have here used HA from either A/turkey/Italy/3889/1999 (H7N1) or A/chicken/Italy/13474/1999 (H7N1) for vaccination, and we observed that both vaccines can confer protection against a viral challenge with A/turkey/Italy/3889/1999 (H7N1). Thus, the induced immune responses can to some extent confer heterologous protection against different H7 strains. Although this cannot at present be generalized to more H7 strains, we also found that vaccination with HA from A/chicken/Italy/13474/1999 (H7N1) raised neutralizing antibodies against A/FPV/Rostock/1934 (H7N1) in a pseudotype-based neutralization assay.

In order to further investigate the mechanisms behind protection, mice vaccinated with Mip1 $\alpha$ -H7 or  $\alpha$ MHCII-H7 were injected with depleting antibodies against CD4<sup>+</sup> and CD8<sup>+</sup> T cells or isotype-matched control antibodies. After challenge with the H7N1 virus, no significant differences were observed in survival between the T-cell-depleted mice and the isotype-treated mice. Although this indicated that cross-reactive antibodies contributed to the protection, T-cell-depleted mice showed a significant increase in morbidity and delayed recovery postchallenge. Presumably, the vaccine induced neutralizing antibodies that could recognize the heterologous virus were below the limiting threshold necessary to mediate complete sterile protection at the given dose. In this situation, a recall of a neutralizing memory B-cell repertoire during the first days of infection likely inhibited ongoing viral infections, but the lack of viral clearance in already infected cells led to some disease manifestations. This observation held true both for mice vaccinated with  $\alpha$ MHCII-H7 and for mice vaccinated with Mip1 $\alpha$ -H7.

Previously, we have demonstrated that targeting of antigen to MHC-II molecules is particularly efficient for induction of antibodies, whereas targeting of antigen to CCR1/3/5 more efficiently will induce T-cell responses (25). After vaccination with A/chicken/Italy/13474/1999 (H7N1) and challenge with A/turkey/Italy/3889/1999 (H7N1), we observed that mice vaccinated with Mip1 $\alpha$ -H7 had a significantly reduced weight loss



compared to  $\alpha$ MHCII-H7. In contrast, we found no significant difference in weight loss between mice vaccinated with  $\alpha$ MHCII-H7 or Mip1 $\alpha$ -H7 when HA from the homologous strain was used. T cells have an increased potential for mediating cross-protection within variations of antigenic drift (34), since T-cell epitopes are more conserved across different subtypes (35). It is therefore likely that increased numbers of IFN- $\gamma$ -secreting T cells and the slight increased CTL response after Mip1 $\alpha$ -H7 vaccination, compared to  $\alpha$ MHCII-H7, can account for the difference in weight loss observed after heterologous challenge. Furthermore, the antibody response after Mip1 $\alpha$ -targeted vaccine delivery is dominated by IgG2a (25). Nonneutralizing H7-specific IgG2a antibodies have also been demonstrated to be protective in mice (36, 37). Antigen-specific antibodies of the IgG2a isotype efficiently induce Fc-receptor-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) (38, 39), complement-dependent cytotoxicity (40, 41), or antibody-dependent cell phagocytosis (42, 43). In addition, ADCC triggering antibodies have been shown to be cross-reactive (44) and might be of particular importance in a pandemic setting (44, 45). In summary, both MHC-II and CCR1/3/5 targeting vaccines induced humoral and cellular responses that contributed to the mode of the observed protection.

Targeting of H7 to APCs consistently increased immune responses, compared to nontargeted controls. Of note, a direct ligation between antigen and targeting unit has been found a prerequisite for efficient induction of immunity (46). It is possible that binding of an APC-targeted vaccine to an APC will improve access to antigenic epitopes and as such promote more efficient binding to B-cell receptors. A stronger and more specific ligation of DCs or B cells might drive an accelerated formation of germinal centers with subsequent isotype switching and affinity maturation. Furthermore, the APC-targeted vaccine could bridge APCs and B cells in a synapse that promotes efficient and mutual activation (47, 48). Furthermore, a synapse formation between an APC and a B cell could lead to B cells sampling antigen from the top, i.e., the head region of HA. This might lead to selection B cells recognizing more neutralizing epitopes in HA resulting in an antibody repertoire with highly neutralizing capacity, as observed with the MHC-II-targeted vaccine.

Our data have clearly demonstrated the benefit of targeting antigen to APCs, particularly when the aim is to induce rapid immune responses to limit the outbreak of pandemic influenza. Previous studies have demonstrated that the immune potentiating effect when targeting to APCs is particularly prominent for weak antigens (28, 32). In contrast, HA from HPAIV H7 is immunogenic in mice, and vaccination with the H7 antigen alone was able to induce modest IgG titers over time. It is possible that avian HAs have increased immunogenicity compared to human HAs due to differences in glycosylation patterns that would stimulate production of immunostimulatory agents in DCs (49). In addition, inactivated influenza viruses with an  $\alpha$ 2,3 preference for sialic acid receptors have been shown to induce higher levels of proinflammatory cytokines in human DCs (18). Thus, HA from HPAIV might trigger an innate immune response that translates into activation of adaptive immunity in mice. However, the antibody levels observed after immunization with nontargeted controls developed significantly more slowly than for the APC-targeted vaccines. Furthermore, the nontargeted controls do not enhance immune responses to the same extent as the APC-targeted vaccines and, most importantly, only APC-targeted vaccines could induce protective immunity, after a single vaccination, toward a lethal challenge with influenza virus.

When using conventional vaccine manufacture for selected avian influenza strains, removal of the MBCS and exchange of certain internal genes is required (4). However, removal of the MBCS can render the virus low pathogenic and poorly immunogenic, compromising vaccine efficacy with obvious implications for vaccine design against pandemic outbreaks (17, 50). Here, we also found that deletion of the MBCS was associated with reduced immunogenicity, which again highlights a benefit of using DNA-based vaccines. Ubiquitous proteases will cleave H7 in the vaccine molecules *in vivo*. Cleavage of HA in the APC-targeted vaccine molecule results in efficient presentation of the native head region in HA1. Vaccines expressed with uncleaved HA0 might

lack some of the essential structural epitopes in HA1 or the HA1-HA2 interface. The majority of protective antibodies bind to the globular head domain of HA. Thus, the cleaved H7 format could more efficiently present epitopes from native HA1, potentially resulting in a more stringent selection of B cells with neutralizing capacity. This effect is probably tissue and species dependent (23, 51), but it is a general benefit from DNA vaccines.

We have here demonstrated that a single DNA vaccination with APC-targeted H7 can confer protection against H7 influenza in mice. No other vaccine format can at present compete with the speed of production and deployment that is possible for DNA vaccines. For prophylactic mass vaccinations, DNA vaccines can be delivered without adjuvant to the dermis by noninvasive needle-free jet delivery systems (26, 52). Ideally, the DNA vaccine should be tailored to precisely match an emerging pandemic strain, which is also a feasible strategy given the short time in which DNA vaccines can be mass produced. The rapid induction of protective antibodies observed when targeting H7 to MHC-II molecules highlights this receptor as particularly interesting for construction of pandemic DNA vaccines. For broader protection, it could be beneficial to target the H7 to chemokine receptors. In summary, we have here demonstrated that DNA delivery of an APC-targeted vaccine could greatly aid the control of an unexpected pandemic threat.

## MATERIALS AND METHODS

**Molecular cloning.** The HA genes from A/chicken/Italy/13474/1999 (H7N1) (aa19-536) and A/turkey/Italy/3889/1999 (H7N1) (aa19-536) were ordered with flanking SfiI sites (GenScript, Piscataway, NJ) and cloned into the previously described hCMV-based pLNO<sub>2</sub> vaccine vectors equipped with targeting units consisting of either a single-chain-variable fragment (scFv) specific for MHC-II (I-E<sup>d</sup>) (32), an scFv specific for the hapten 4-hydroxy-3-iodo-5-nitrophenylacetic acid (NIP) (nontargeted control) (32), or the macrophage inflammatory protein 1 $\alpha$  (Mip-1 $\alpha$ ) (25, 28). In another vaccine construct, the multibasic cleavage site (aa340-343) was removed from HA (H7 $\Delta$ ), and the gene was cloned into a vaccine vector with an MHC-II-specific scFv. In addition, a vaccine construct encoding only HA was constructed by introduction of an upstream BsmI restriction site with primers the 5'-GGTGTGCATTCCGGCCTCGGTG and 3'-GTGGATCCTCTAGATCGACGGACCGGC (the BsmI site and the start of the SfiI site are underlined).

**Assessment of *in vitro* expressed vaccine proteins.** An influenza A H7N9 (A/Shanghai/1/2013) hemagglutinin ELISA pair set (SEK40104; Sino Biological, Inc., North Wales, PA) was used. Briefly, ELISA plates (Costar 3590; Corning, Corning, NY) were coated with 0.5  $\mu$ g/ml rabbit anti-HA monoclonal antibody (MAb), blocked with 1% bovine serum albumin (BSA), and incubated with supernatants from 293E cells transfected with 1- $\mu$ g vaccine plasmids and 2  $\mu$ g of polyethylenimine (PEI). Vaccine proteins were detected with horseradish peroxidase-conjugated anti-HA pAb (1  $\mu$ g/ml) and 3,3',5,5'-tetramethylbenzidine (TMB) substrate (CL07; Merck Millipore, San Diego, CA). The reaction was stopped after 20 min of incubation with an equal volume of 0.5 M H<sub>2</sub>SO<sub>4</sub>, and the plates were read at 450 nm with a Tecan reader (Tecan, Switzerland) using Magellan v5.03 software.

Vaccine proteins were produced by transient transfection of 293E cells with PEI. Constructs containing the C<sub>1</sub>3 domain were purified on a CaptureSelect FcXL affinity column (catalog no. 194328005; Life Technologies, Naarden, The Netherlands). Splenocytes were harvested from BALB/c mice, and single cell suspensions were Fc $\gamma$ R blocked by incubation with 30% heat-inactivated rat serum and stained with purified vaccine proteins, CD3-VF450 (catalog no. 75-0032; Tonbo Biosciences, San Diego, CA), CD19-FITC (catalog no. 35-0193; Tonbo Biosciences), CD11b-PerCP/Cy5.5 (catalog no. 65-0112; Tonbo Biosciences), CD11c-PE/Cy7 (catalog no. 117318; BioLegend, San Diego, CA), F4/80-AF700 (catalog no. 123130; BioLegend), and CD64-APC (catalog no. 139306; BioLegend), followed by hCH3-PE (catalog no. 409304, BioLegend). Cells were analyzed on an Attune NxT flow cytometer (Thermo Fisher Scientific, Waltham, MA) and FlowJo software.

**Western blotting.** Vaccine plasmids were transiently transfected into 293E cells as described above. Supernatants were up-concentrated (VivaSpin 500, MWCO 10000; Sartorius, Gottingen, Germany) and denatured in sodium dodecyl sulfate sample buffer at 95°C for 5 min. The samples were then run on a Bolt 4 to 12% Bis-Tris Plus gel (NW04122BOX; Novex, Carlsbad, CA), blotted onto a polyvinylidene difluoride (PVDF) membrane (catalog no. IB24001, iBlot transfer stack; Invitrogen, Kiryat Shmona, Israel), blocked in 2% skimmed milk, and detected by using monoclonal (Fig. 1) or polyclonal (Fig. 2) rabbit  $\alpha$ H7 antibodies (SEK40104; Sino Biological). Next, the membrane was incubated with polyclonal goat anti-rabbit IgG conjugated to alkaline phosphatase (ALP; A3687; Sigma-Aldrich) and developed with the BCIP/NBT-Purple Liquid substrate system for membranes (B3679; Sigma-Aldrich).

**Mice and cell lines.** Cell work was performed with human embryonic kidney 293E cells purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). Six- to eight-week-old female BALB/c or CB6F1 mice (Janvier, le Genest-Saint-Isle, France) were used in all experiments. The animals were housed under minimal disease conditions, and all animal experiments were preapproved by the Norwegian Animal Research Authority.

**Vaccination.** Mice were anesthetized (0.1 mg/10 g [body weight] with a cocktail composed of Zoletil Forte [250 mg/ml; Virbac France], Rompun [20 mg/ml; Bayer Animal Health GmbH], and fentanyl [50 µg/ml; Actavis, Germany]) by intraperitoneal (i.p.) injection. For i.d. delivery of vaccines, the lower back region of each mouse was shaved, and 12.5 µg of plasmid in a 25-µl volume was injected at two sites (total DNA/mouse, 25 µg), immediately followed by skin electroporation (DermaVax; Cellectis, Paris, France). For i.m. delivery of vaccines, mice were shaved on each leg, and 6.25 µg of DNA was injected in a 50-µl volume into each quadriceps femoris (total DNA/mouse, 12.5 µg). Immediately after injection, electrical pulses were applied at the injection site (Elgen; Inovio Biomedical Co., Blue Bell, PA). All DNA vaccines were purified by using an EndoFree Plasmid Mega kit (catalog no. 12381; Qiagen, Hilden, Germany) and dissolved in sterile injection fluid (0.9% NaCl).

**Serum ELISA.** Blood was harvested by puncture of the saphenous vein, and sera were isolated by centrifugation. ELISA plates (Costar 3590) were coated with 0.5 µg/ml recombinant HA [A/Shanghai/1/2013 (H7N9)] (40104-V08B; Sino Biological), blocked with 1% BSA, and incubated with serially diluted serum samples assayed individually ( $n = 6$  to 12/group). HA-specific antibodies were detected with alkaline phosphatase conjugated goat anti-mouse IgG (A1418; Sigma-Aldrich), developed with phosphatase substrate (P4744; Sigma-Aldrich) and analyzed as previously described. For all serum ELISAs, titers were determined as the last serum dilution with an optical density at 405 nm above background (the mean absorbance from NaCl-vaccinated mice added five times the standard error of the mean for the group).

**Pseudotype-based neutralizing assay.** Pseudotyped virus was prepared and quantified as previously reported (53). Briefly,  $3 \times 10^3$  MDCK cells were seeded in each well of a 96-well culture plate (Corning) and incubated overnight at 37°C in 5% CO<sub>2</sub> and saturated humidity. Then, serially diluted serum samples, pooled by group, that had been preincubated with HA and NA pseudotypes from A/FPV/Rostock/1934 (H7N1) (2,000 to 200,000 relative luciferase activity [RLA]) at 37°C in 5% CO<sub>2</sub> and saturated humidity for 1 h were added to the cells for 72 h of incubation at 37°C in 5% CO<sub>2</sub> and saturated humidity. The RLA values were measured by a BrightGlo luciferase assay according to the manufacturer's instructions (Promega, Madison, WI). The percent inhibition was calculated as follows: (RLA in pseudotypes and medium control – RLA in pseudotypes and immune serum at a given dilution)/RLA in pseudotypes and medium control. The data were fitted to a sigmoidal dose-response curve using GraphPad Prism 6 software, and IC<sub>50</sub> and IC<sub>90</sub> values were determined from those data sets.

**ELISPOT assay.** Mouse IFN-γ ELISPOT Plus plates (3321-4APT; Mabtech, Nacka Strand, Sweden) were blocked with RPMI plus 10% fetal calf serum for 2 h at 37°C in 5% CO<sub>2</sub>. Mouse spleens were harvested at 8 weeks postinfection, and single cell suspensions were prepared with a gentleMACS dissociator (Milteny Biotec, Bergisch Gladbach, Germany), followed by incubation in ACT lysis buffer for 5 min on ice. Next,  $0.5 \times 10^6$  cells were seeded per well, and cells were stimulated with either medium (negative control), ConA (1 µg/ml, positive control), or 10 µg/ml recombinant HA from either A/Shanghai/1/2013 (H7N9), or A/Puerto Rico/8/1934 (H1N1), or A/Vietnam/1194/2004 (H5N1) (40104-V08B, 11684-V08H, and 11062-V08H1, respectively; Sino Biological). Plates were incubated for 20 h at 37°C in 5% CO<sub>2</sub> before incubation with the detection antibody (3321-4APT; Mabtech) and development with the BCIP/NBT-Purple liquid substrate system for membranes (B3679; Sigma-Aldrich). Plates were analyzed with the CTL-ImmunoSpot analyzer (CTL, Shaker Heights, OH).

**In vivo killing assay.** A20 cells expressing cytosolic H7 and GFP, as well as control cells expressing mCherry, were created by retroviral transduction, followed by selection of highly expressing cells by fluorescence-activated cell sorting. H7 GFP cells and mCherry cells ( $5 \times 10^6$ ; 1:1) were injected intravenously (i.v.) into BALB/c mice, and the prevalence of GFP-positive and mCherry-positive cells in the spleen were analyzed 16 h later in an Attune NxT flow cytometer (Thermo Fisher Scientific, Waltham, MA) using FlowJo software. Killing ratios were calculated by defining the average ratio between the two cell lines in the NaCl group as 0% killing and finding no H7 GFP cells as 100% killing.

**Viral challenge.** Mice were anesthetized as described previously and inoculated with  $20 \times$  LD<sub>50</sub> mouse-adapted A/turkey/Italy/3889/1999 (H7N1) in 10 µl/nostril. Mice were monitored for weight loss, and mice that lost >20% of the original body weight were euthanized by cervical dislocation.

**H&E staining of lung sections.** Formalin-fixed lungs were embedded in paraffin, sectioned, and stained with H&E. Sections were mounted using Dako toluene-free mounting medium (CS705; Dako, Santa Clara, CA). Micrographs of tissue sections were collected using Nikon Eclipse Ti-S microscope (Nikon Corporation, Tokyo, Japan), and a 10×/0.30 objective lens.

**T-cell depletion.** Mice ( $n = 10/n = 8$  [NaCl group]) were vaccinated once i.d. as previously described. Two days prior to challenge and then every other day until completion of the experiment, 200 µg of anti-CD4 MAb (GK1.5; ATCC) and 200 µg of anti-CD8 MAb (TIB105; ATCC), or control MAbs (200 µg of SRF8-B6 and 200 µg of Y13-238) (23), were injected i.p. into the mice. At the end of the experiment, the spleens were harvested to assess T-cell depletion. Briefly, single cell suspensions were prepared, and cells stained with fluorescein isothiocyanate-conjugated anti-mouse CD3e (catalog no. 35-0031; Tonbo Biosciences), PerCP-Cy5.5-conjugated rat anti-mouse CD45R (catalog no. 552771; BD Pharmingen), APC-conjugated rat anti-mouse CD4 (catalog no. 1540-11; Southern Biotech Associates, Birmingham, AL), and PE-conjugated rat anti-mouse CD8a (553033; BD Pharmingen). For background assessments, the following isotype controls were used: APC-conjugated rat IgG2b (catalog no. 0118-11; Southern Biotech Associates, Birmingham, AL) and PE-conjugated rat IgG2a (catalog no. 553930; BD Pharmingen). The data were analyzed with FlowJo 10.2 software. Representative flow panels of the stained splenocytes are shown in Fig. S3 in the supplemental material. The degree of depletion was >99%.

**Statistical analysis.** *P* values represent exact values calculated by unpaired nonparametric two-tailed Mann-Whitney tests. Data treated with sigmoidal fitting software are represented with *P* values from the

comparison by the extra sum-of-squares F test to determine significance of the inhibitory concentration (IC) levels. Correlation was computed using nonparametric Spearman correlation and represented with a two-tailed *P* value. Weight curves were analyzed with two-way analysis of variance (ANOVA), and survival curves were analyzed with the Gehan-Breslow-Wilcoxon test. All analyses were performed using GraphPad Prism 6 software.

## ACKNOWLEDGMENTS

We thank Harvard Apparatus BTX for providing the skin electroporator and Inovio Biomedical for providing the muscle electroporator. The technical help of Elisabeth Vikse is gratefully acknowledged. We thank the National Institute of Biological Sciences (NIBSC), United Kingdom, for providing the influenza H7 strains. We especially thank Paul Zhou, Institute Pasteur of Shanghai CAS, China, for the development and provision of constructs for the pseudotype assay.

B.B. and G.G. are inventors on patent applications filed on the vaccine molecules by the TTO offices of the University of Oslo and Oslo University Hospital, according to institutional rules. B.B. is head of the scientific panel of Vaccibody AS and holds shares in the company.

T.K.A., F.Z., R.C., B.B., and G.G. conceived and designed experiments. T.K.A., F.Z., and G.G. performed experiments. T.K.A., F.Z., R.C., B.B., and G.G. analyzed the experiments. T.K.A., B.B., and G.G. wrote the paper, but all authors contributed comments and editing.

## REFERENCES

- World Health Organization. 2017. Influenza at the human-animal interface, June 2017: monthly risk assessment summary, p 1–7. World Health Organization, Geneva, Switzerland.
- Fouchier RaM, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SaG, Munster V, Kuiken T, Rimmelzwaan GF, Schutten M, Van Doornum GJJ, Koch G, Bosman A, Koopmans M, Osterhaus ADME. 2004. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. *Proc Natl Acad Sci U S A* 101:1356–1361. <https://doi.org/10.1073/pnas.0308352100>.
- Zanin M, Koçer ZA, Poulson RL, Gabbard JD, Howerth EW, Jones CA, Friedman K, Seiler J, Danner A, Kercher L, McBride R, Paulson JC, Wentworth DE, Krauss S, Tompkins SM, Stallknecht DE, Webster RG. 2016. The potential for low pathogenic avian H7 influenza viruses to replicate and cause disease in a mammalian model. *J Virol* 91:e01934-16. <https://doi.org/10.1128/JVI.01934-16>.
- Krammer F, Palese P. 2015. Advances in the development of influenza virus vaccines. *Nat Rev Drug Discov* 14:167–182. <https://doi.org/10.1038/nrd4529>.
- Zhou L, Ren R, Yang L, Bao C, Wu J, Wang D, Li C, Xiang N, Wang Y, Li D, Sui H, Shu Y, Feng Z, Li Q, Ni D. 2017. Sudden increase in human infection with avian influenza A(H7N9) virus in China, September–December 2016. *Western Pac Surveill Response J* 8:6–14. <https://doi.org/10.5365/wpsar.2017.8.1.001>.
- Bavagnoli L, Maga G. 2011. The 2009 influenza pandemic: promising lessons for antiviral therapy for future outbreaks. *Curr Med Chem* 18:5466–5475. <https://doi.org/10.2174/092986711798194397>.
- De Groot AS, Moise L, Liu R, Gutierrez AH, Terry F, Koita OA, Ross TM, Martin W. 2014. Cross-conservation of T-cell epitopes now even more relevant to (H7N9) influenza vaccine design. *Hum Vaccin Immunother* 10:256–262. <https://doi.org/10.4161/hv.28135>.
- Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li XX, Zou S, Zhang YY, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y. 2013. Human infection with a novel avian-origin influenza A (H7N9) virus. *N Engl J Med* 368:1888–1897. <https://doi.org/10.1056/NEJMoa1304459>.
- Imai M, Kawaoka Y. 2012. The role of receptor binding specificity in interspecies transmission of influenza viruses. *Curr Opin Virol* 2:160–167. <https://doi.org/10.1016/j.coviro.2012.03.003>.
- Tumpey TM, Maines TR, Hoeven NV, Glaser L, Solórzano A, Pappas C, Cox NJ, Swayne DE, Palese P, Katz JM, García-Sastre A. 2007. A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. *Science* 315:655–659. <https://doi.org/10.1126/science.1136212>.
- Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. 2004. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. *Proc Natl Acad Sci U S A* 101:4620–4624. <https://doi.org/10.1073/pnas.0308001101>.
- Belser JA, Blixt O, Chen LM, Pappas C, Maines TR, Van Hoeven N, Donis R, Busch J, McBride R, Paulson JC, Katz JM, Tumpey TM. 2008. Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility. *Proc Natl Acad Sci U S A* 105:7558–7563. <https://doi.org/10.1073/pnas.0801259105>.
- Ramos I, Krammer F, Hai R, Aguilera D, Bernal-Rubio D, Steel J, García-Sastre A, Fernandez-Sesma A. 2013. H7N9 influenza viruses interact preferentially with  $\alpha$ 2,3-linked sialic acids and bind weakly to  $\alpha$ 2,6-linked sialic acids. *J Gen Virol* 94:2417–2423. <https://doi.org/10.1099/vir.0.056184-0>.
- Zhou J, Wang D, Gao R, Zhao B, Song J, Qi X, Zhang Y, Shi Y, Yang L, Zhu W, Bai T, Qin K, Lan Y, Zou S, Guo J, Dong J, Dong L, Zhang Y, Wei H, Li X, Lu J, Liu L, Zhao X, Li X, Huang W, Wen L, Bo H, Xin L, Chen Y, Xu C, Pei Y, Yang Y, Zhang X, Wang S, Feng Z, Han J, Yang W, Gao GF, Wu G, Li D, Wang Y, Shu Y. 2013. Biological features of novel avian influenza A (H7N9) virus. *Nature* 499:500–503. <https://doi.org/10.1038/nature12379>.
- Reperant LA, Kuiken T, Osterhaus AD. 2012. Adaptive pathways of zoonotic influenza viruses: From exposure to establishment in humans. *Vaccine* 30:4419–4434. <https://doi.org/10.1016/j.vaccine.2012.04.049>.
- Gohrbandt S, Veits J, Hundt J, Bogs J, Breithaupt A, Teifke JP, Weber S, Mettenleiter TC, Stech JR. 2011. Amino acids adjacent to the haemagglutinin cleavage site are relevant for virulence of avian influenza viruses of subtype H5. *J Gen Virol* 92:51–59. <https://doi.org/10.1099/vir.0.023887-0>.
- Jr SA, Matsuoka Y, Lau Y-F, Santos CP, Vogel L, Cheng LI, Orandle M, Subbarao K. 2012. The multibasic cleavage site of the hemagglutinin of highly pathogenic A/Vietnam/1203/2004 (H5N1) avian influenza virus acts as a virulence factor in a host-specific manner in mammals. *J Virol* 86:2706–2714. <https://doi.org/10.1128/JVI.05546-11>.
- Ramos I, Bernal-Rubio D, Durham N, Belicha-Villanueva A, Lowen AC, Steel J, Fernandez-Sesma A. 2011. Effects of receptor binding specificity of avian influenza virus on the human innate immune response. *J Virol* 85:4421–4431. <https://doi.org/10.1128/JVI.02356-10>.
- Wilks S, de Graaf M, Smith DJ, Burke DF. 2012. A review of influenza haemagglutinin receptor binding as it relates to pandemic properties. *Vaccine* 30:4369–4376. <https://doi.org/10.1016/j.vaccine.2012.02.076>.
- Guo XL, Li L, Wei DQ, Zhu YS, Chou KC. 2008. Cleavage mechanism of the



- H5N1 hemagglutinin by trypsin and furin. *Amino Acids* 35:375–382. <https://doi.org/10.1007/s00726-007-0611-3>.
21. Stech O, Veits J, Weber S, Deckers D, Schröder D, Vahlenkamp TW, Breithaupt A, Teifke J, Mettenleiter TC, Stech J. 2009. Acquisition of a polybasic hemagglutinin cleavage site by a low-pathogenic avian influenza virus is not sufficient for immediate transformation into a highly pathogenic strain. *J Virol* 83:5864–5868. <https://doi.org/10.1128/JVI.02649-08>.
  22. Stieneke-Gröber A, Vey M, Angliker H, Shaw E, Thomas G, Roberts C, Klenk HD, Garten W. 1992. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. *EMBO J* 11:2407–2414.
  23. Galloway SE, Reed ML, Russell CJ, Steinhauer DA. 2013. Influenza HA subtypes demonstrate divergent phenotypes for cleavage activation and pH of fusion: implications for host range and adaptation. *PLoS Pathog* 9:e1003151. <https://doi.org/10.1371/journal.ppat.1003151>.
  24. Grødeland G, Mjaaland S, Roux KH, Fredriksen AB, Bogen B. 2013. DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza. *J Immunol* 191:3221–3231. <https://doi.org/10.4049/jimmunol.1300504>.
  25. Grødeland G, Mjaaland S, Tunheim G, Fredriksen AB, Bogen B. 2013. The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype. *PLoS One* 8:e80008. <https://doi.org/10.1371/journal.pone.0080008>.
  26. Grødeland G, Fredriksen AB, Løset GÅ, Vikse E, Fugger L, Bogen B. 2016. Antigen targeting to human HLA class II molecules increases efficacy of DNA vaccination. *J Immunol* 197:3575–3585. <https://doi.org/10.4049/jimmunol.1600893>.
  27. Biragyn A, Ruffini PA, Coscia M, Harvey LK, Neelapu SS, Baskar S, Wang JM, Kwak LW. 2004. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. *Blood* 104:1961–1969. <https://doi.org/10.1182/blood-2004-02-0637>.
  28. Fredriksen AB, Bogen B. 2007. Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. *Blood* 110:1797–1805. <https://doi.org/10.1182/blood-2006-06-032938>.
  29. Menten P, Wuyts A, Van Damme J. 2002. Macrophage inflammatory protein-1. *Cytokine Growth Factor Rev* 13:455–481. [https://doi.org/10.1016/S1359-6101\(02\)00045-X](https://doi.org/10.1016/S1359-6101(02)00045-X).
  30. Ruffini PA, Biragyn A, Coscia M, Harvey LK, Cha S-C, Bogen B, Kwak LW. 2004. Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. *J Leukoc Biol* 76:77–85. <https://doi.org/10.1189/jlb.1003481>.
  31. Schiavo R, Baatar D, Olkhanud P, Indig FE, Restifo N, Taub D, Biragyn A. 2006. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8<sup>+</sup> T-cell responses. *Blood* 107:4597–4605. <https://doi.org/10.1182/blood-2005-08-3207>.
  32. Fredriksen AB, Sandlie I, Bogen B. 2006. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. *Mol Ther* 13:776–785. <https://doi.org/10.1016/j.ymthe.2005.10.019>.
  33. Baz M, Luke CJ, Cheng X, Jin H, Subbarao K. 2013. H5N1 vaccines in humans. *Virus Res* 178:78–98. <https://doi.org/10.1016/j.virusres.2013.05.006>.
  34. Guo H, Santiago F, Lambert K, Takimoto T, Topham DJ. 2011. T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. *J Virol* 85:448–455. <https://doi.org/10.1128/JVI.01812-10>.
  35. Jameson J, Cruz J, Terajima M, Ennis FA. 1999. Human CD8<sup>+</sup> and CD4<sup>+</sup> T lymphocyte memory to influenza A viruses of swine and avian species. *J Immunol* 162:7578–7583.
  36. Dunand CJH, Leon PE, Huang M, Choi A, Chromikova V, Ho IY, Tan GS, Cruz J, Hirsh A, Zheng NY, Mullarkey CE, Ennis FA, Terajima M, Treanor JJ, Topham DJ, Subbarao K, Palese P, Krammer F, Wilson PC. 2016. Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. *Cell Host Microbe* 19:800–813. <https://doi.org/10.1016/j.chom.2016.05.014>.
  37. Tan GS, Leon PE, Albrecht RA, Margine I, Hirsh A, Bahl J, Krammer F. 2016. Broadly reactive neutralizing and non-neutralizing antibodies directed against the H7 influenza virus hemagglutinin reveal divergent mechanisms of protection. *PLoS Pathog* 12:e1005578. <https://doi.org/10.1371/journal.ppat.1005578>.
  38. Akiyama Y, Lubeck MD, Steplewski Z, Koprowski H. 1984. Induction of mouse IgG2a- and IgG3-dependent cellular cytotoxicity in human monocytic cells (U937) by immune interferon. *Cancer Res* 44:5127–5131.
  39. Nimmerjahn F, Lux A, Albert H, Woigk M, Lehmann C, Dudziak D, Smith P, Ravetch JV. 2010. FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. *Proc Natl Acad Sci U S A* 107:19396–19401. <https://doi.org/10.1073/pnas.1014515107>.
  40. Neuberger MS, Rajewsky K. 1981. Activation of mouse complement by monoclonal mouse antibodies. *Eur J Immunol* 11:1012–1016. <https://doi.org/10.1002/eji.1830111212>.
  41. Terajima M, Cruz J, Co MDT, Lee J-H, Kaur K, Wrammert J, Wilson PC, Ennis FA. 2012. Complement-dependent lysis of influenza A virus-infected cells by broadly cross-reactive human monoclonal antibodies. *J Virol* 86:1901–1901. <https://doi.org/10.1128/JVI.06884-11>.
  42. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. 2001. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. *J Immunol* 166:7381–7388. <https://doi.org/10.4049/jimmunol.166.12.7381>.
  43. Unkeless JC, Eisen HN. 1975. Binding of monomeric immunoglobulins to Fc receptors of mouse macrophages. *J Exp Med* 142:1520–1533. <https://doi.org/10.1084/jem.142.6.1520>.
  44. Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, De Rose R, Winnall WR, Stratov I, Brooks AG, Reading PC, Kent SJ. 2013. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. *J Immunol* 190:1837–1848. <https://doi.org/10.4049/jimmunol.1201574>.
  45. Jegaskanda S, Laurie KL, Amarasekera TH, Winnall WR, Kramski M, De Rose R, Barr IG, Brooks AG, Reading PC, Kent SJ. 2013. Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. *J Infect Dis* 208:1051–1061. <https://doi.org/10.1093/infdis/jit294>.
  46. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. 1999. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. *Nat Biotechnol* 17:253–258. <https://doi.org/10.1038/6995>.
  47. Batista FD, Iber D, Neuberger MS. 2001. B cells acquire antigen from target cells after synapse formation. *Nature* 411:489–494. <https://doi.org/10.1038/35078099>.
  48. Fredriksen AB, Sandlie I, Bogen B. 2012. Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. *Front Oncol* 2:154. <https://doi.org/10.3389/fonc.2012.00154>.
  49. Liu WC, Lin YL, Spearman M, Cheng PY, Butler M, Wu SC. 2016. Influenza hemagglutinin glycoproteins with different N-glycan patterns activate dendritic cells *in vitro*. *J Virol* 90:6085–6096. <https://doi.org/10.1128/JVI.00452-16>.
  50. Jr SA, Marino MP, Desai PD, Chen LM, Matsuoka Y, Donis RO, Jin H, Swayne DE, Kemble G, Subbarao K. 2009. The influence of the multibasic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus. *Virology* 395:280–288. <https://doi.org/10.1016/j.virol.2009.09.017>.
  51. Zhirnov OP, Ikizler MR, Wright PF. 2002. Cleavage of influenza A virus hemagglutinin in human respiratory epithelium is cell associated and sensitive to exogenous antiproteases. *J Virol* 76:8682–8689. <https://doi.org/10.1128/JVI.76.17.8682-8689.2002>.
  52. Manam S, Ledwith BJ, Barnum AB, Troilo PJ, Pauley CJ, Harper LB, Griffiths TG, Niu Z, Denisova L, Follmer TT, Pacchione SJ, Wang Z, Beare CM, Bagdon WJ, Nichols WW. 2000. Plasmid DNA vaccines: Tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. *Intervirology* 43:273–281. <https://doi.org/10.1159/000053994>.
  53. Tsai C, Caillet C, Hu H, Zhou F, Ding H, Zhang G, Zhou B, Wang S, Lu S, Buchy P, Deubel V, Vogel FR, Zhou P. 2009. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. *Vaccine* 27:6777–6790. <https://doi.org/10.1016/j.vaccine.2009.08.056>.